|
注册号: Registration number: |
ChiCTR2600123294 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-23 16:55:34 |
|
注册时间: Date of Registration: |
2026-04-23 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于物联网技术的呼吸康复方案在微创肺切除术患者中的效果评价:一项前瞻性、单中心、随机、开放平行临床研究 |
|
Public title: |
Evaluation of an IoT-baced respiratory rehabilitation program in pations with minimally invasive lobectomy :a prospective, single-center , randomized, open parallel clinical study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于物联网技术的呼吸康复方案在微创肺切除术患者中的效果评价:一项前瞻性、单中心、随机、开放平行临床研究 |
|
Scientific title: |
Evaluation of an IoT-baced respiratory rehabilitation program in pations with minimally invasive lobectomy :a prospective, single-center , randomized, open parallel clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杭琳 |
研究负责人: |
张洁苹 |
|
Applicant: |
Lin Hang |
Study leader: |
Jieping Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 195 5021 7189 |
研究负责人电话:
Study leader's |
+86 138 5710 8886 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hl9627@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zjppxwk@zju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市庆春路79号 |
研究负责人通讯地址: |
浙江省杭州市庆春路79号 |
|
Applicant address: |
79 Qingchun Road, Hangzhou 31003, Zhejiang, China |
Study leader's address: |
79 Qingchun Road, Hangzhou 31003, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
347453 |
研究负责人邮政编码: Study leader's postcode: |
347453 |
|
申请人所在单位: |
浙江大学医学院附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Zhejiang University School of Medicine |
||
|
研究负责人所在单位: |
浙江大学医学院附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Zhejiang University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
浙大一院伦审2024研第092号-会 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江大学医学院附属第一医院IIT伦理审查委员会 |
||
|
Name of the ethic committee: |
IIT Ethics Review Committee of the First Affiliated Hospital, Zhejiang University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-13 00:00:00 | ||
|
伦理委员会联系人: |
殷琳 |
||
|
Contact Name of the ethic committee: |
Yin Lin |
||
|
伦理委员会联系地址: |
浙江省杭州市庆春路79号 |
||
|
Contact Address of the ethic committee: |
79 Qingchun Road, Hangzhou 31003, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 571 8723 3418 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
浙江大学医学院附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Zhejiang University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市庆春路79号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
79 Qingchun Road, Hangzhou 31003, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
经费来源-医疗器械由产家免费提供 其他产生的费用来自于课题经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Medical devices are provided free of charge by the manufacturer. All other associated costs are covered by the project funding. |
||||||||||||||||||||||
|
研究疾病: |
肺癌 |
||||||||||||||||||||||
|
Target disease: |
lung cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
与呼吸操锻炼组比较,评价基于物联网技术呼吸康复方案在肺切除手术患者肺功能改善中的干预效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
Compared with the respiratory exercise group, evaluate the intervention effect of IoT based respiratory rehabilitation program on improving lung function in patients undergoing lung resection surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
(实验组)基于物联网的呼吸康复管理组:除接受加速康复护理外,采用基于物联网的呼吸康复于物联网的呼吸康复组或吹气球锻炼组),进行围手术期管理,按计划行肺叶或亚肺叶切除。 管理,设备涉及后台的中央监护、赛客小鲲呼吸训练器以及便携式肺功能仪,它是一款医疗级智能硬件设备。提供呼吸训练+气道廓清+数据分析,全程AI语音交互,支持自动训练模式,可智能调节阻力。同时可以互联赛客呼吸训练中央监护平台,训练数据自动采集,实时上传至中央监护平台,同时可互联赛客呼吸训练管理系统,实现全方位呼吸康复。患者可以通过微信群和医护人员进行沟通,医护人员可以随时监督患者的训练情况,并及时进行指导和干预,提高患者的依从性和参与度。 (对照组)呼吸操锻炼组:除接受加速康复护理外,增加呼吸操的指导等,术后每天指导监督患者进行呼吸操锻炼,同时在出院后1月内,微信群每日监督患者锻炼情况。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Experimental Group - IoT-Based Respiratory Rehabilitation Management Group:** In addition to receiving enhanced recovery after surgery (ERAS) nursing care, patients underwent perioperative management with IoT-based respiratory rehabilitation (replacing the balloon-blowing exercise group) and proceeded according to plan with lobectomy or sublobectomy. The management utilized devices including a central monitoring system, the Saike Xiaokun respiratory trainer, and a portable pulmonary function meter—a medical-grade smart hardware device. It offers respiratory training + airway clearance + data analysis, with full AI voice interaction, supports automatic training modes, and intelligently adjusts resistance. It can also be linked to the Saike Respiratory Training Central Monitoring Platform, where training data is automatically collected and uploaded in real time, and integrated with the Saike Respiratory Training Management System for comprehensive respiratory rehabilitation. Patients could communicate with healthcare staff via a WeChat group, allowing medical personnel to monitor patients’ training progress at any time, provide timely guidance and intervention, and enhance patient compliance and engagement. Control Group - Respiratory Exercise Group: In addition to receiving enhanced recovery after surgery (ERAS) nursing care, patients were provided with guidance on respiratory exercises. They were instructed and supervised daily in performing respiratory exercises after surgery, and their exercise adherence was monitored daily via a WeChat group during the first month after discharge. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 术前戒烟时间小于 2 周; 2. 术前患者功能状况评分(ECOG 评分)大于 1 分; 3. 接受过术前新辅助治疗的患者; 4. 既往接受过胸部外科手术的患者; 5. 有证据显示术前 1 月内持续使用全身皮质激素; 6. 在开始研究治疗时,任何既往治疗未解决的毒性大于 CTCAE 1 级; 7. 既往有重大疾病史,包括 5 年内其他恶性肿瘤史,6 个月内心绞痛、心肌梗塞、脑卒中史; 8. 有证据显示当前存在严重或不可控的全身疾病,包括甲状腺疾病、不可控的高血压,凝血功能障碍或活动性感染,包括乙型肝炎、丙型肝炎和人体免疫 缺陷病毒(HIV)等; 9. 经研究者判断患者其他不适宜纳入研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Smoking cessation time before surgery is less than 2 weeks; 2. Preoperative patient functional status score (ECOG score) is greater than 1 point; 3. Patients who have received preoperative neoadjuvant therapy; 4. Patients who have undergone chest surgery in the past; 5. There is evidence to suggest continuous use of systemic corticosteroids within one month prior to surgery; 6. At the beginning of the treatment study, any unresolved toxicity from previous treatments is greater than CTCAE grade 1; 7. Having a history of major illnesses in the past, including a history of other malignant tumors within 5 years, and a history of angina pectoris, myocardial infarction, and stroke within 6 months; 8. There is evidence to suggest the existence of serious or uncontrollable systemic diseases, including thyroid disease, uncontrolled hypertension, coagulation dysfunction, or active infections, such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV); 9. According to the researcher's judgment, there are other situations where the patient is not suitable for inclusion in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-05 00:00:00 至 To 2026-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
运用SAS 9.4(或更高版本)统计软件,采用区组随机化的方法,按试验组和对照组1:1的比例产生连续编号的受试者随机编码表。受试者在研究期间分配唯一的随机号。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using SAS 9.4 (or higher) statistical software, a block randomization method is employed to generate a sequentially numbered subject randomization code table with a 1:1 allocation ratio between the experimental and control groups. Each subject is assigned a unique randomization number for the duration of the study. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究公开发表后半年,邮件联系研究负责人合理获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the publication of the research, contact the research leader via email to obtain reasonable information. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
利用后台数据管理管理病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Utilize background data management to administer case report forms. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |